STOCK TITAN

[SCHEDULE 13G/A] Apollomics Inc. Warrant SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Apollomics Inc. Schedule 13G/A filed by Maxpro Investment Co., Ltd discloses that the reporting person beneficially owns 105,071 Class A ordinary shares, representing 4.90% of the Class A shares outstanding based on 2,146,151 shares. The total includes 101,248 currently outstanding Class A shares and 3,823 Class A shares issuable upon exercise of warrants exercisable within 60 days of this filing. The filing states that on September 3, 2025 the issuer completed a private placement of 1,042,803 Class A shares, after which Maxpro ceased to be a beneficial owner of more than 5% of the Class A shares; this amendment is an exit filing reflecting that change.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Maxpro now holds 4.90% after issuer's private placement; this amendment documents an exit below 5% ownership.

This Schedule 13G/A confirms that Maxpro Investment Co., Ltd beneficially owns 105,071 Class A ordinary shares of Apollomics, including 3,823 shares from exercisable warrants. The filing explains the decline in ownership stake was driven by a private placement of 1,042,803 Class A shares on September 3, 2025, increasing the issuer's outstanding share base to 2,146,151 and reducing Maxpro's percentage below the 5% reporting threshold. The statement is presented as an exit amendment and includes the cover page voting and dispositive powers showing sole voting and dispositive power over 105,071 shares.

TL;DR: Amendment documents a routine ownership dilution disclosure after a material private placement.

The amendment emphasizes compliance with beneficial ownership reporting rules: it itemizes share composition (101,248 owned plus 3,823 warrant-issuable) and cites the change in percentage ownership resulting from the issuer's private placement. The filing includes certification language attesting to ordinary-course holdings and comparable foreign regulatory treatment for the reporting entity. This is a disclosure of ownership dilution rather than a new acquisition or control change.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Maxpro Investment Co., Ltd
Signature:/s/ Yi Kuei Chen
Name/Title:Yi Kuei Chen / Director
Date:09/05/2025
APOLLOMICS INC

NASDAQ:APLMW

APLMW Rankings

APLMW Latest News

APLMW Latest SEC Filings

APLMW Stock Data

1.78M
1.10M